Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ikena Oncology, Inc. (IKNA)

2.23   -0.13 (-5.51%) 12-05 16:00
Open: 2.3 Pre. Close: 2.36
High: 2.47 Low: 2.23
Volume: 67,678 Market Cap: 81(M)

Technical analysis

as of: 2022-12-06 7:48:56 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.99     One year: 3.44
Support: Support1: 1.94    Support2: 1.61
Resistance: Resistance1: 2.56    Resistance2: 2.95
Pivot: 2.28
Moving Average: MA(5): 2.34     MA(20): 2.26
MA(100): 3.84     MA(250): 5.88
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 68.2     %D(3): 68.4
RSI: RSI(14): 42.5
52-week: High: 16.63  Low: 1.94
Average Vol(K): 3-Month: 79 (K)  10-Days: 40 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IKNA ] has closed above bottom band by 40.7%. Bollinger Bands are 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.47 - 2.49 2.49 - 2.5
Low: 2.2 - 2.21 2.21 - 2.23
Close: 2.21 - 2.23 2.23 - 2.25

Company Description

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 30 Nov 2022
Ikena Oncology's Return On Capital Employed Insights - Ikena Oncology (NASDAQ:IKNA) - Benzinga

Mon, 28 Nov 2022
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update - Yahoo Finance

Mon, 07 Nov 2022
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates - Zacks Investment Research

Wed, 26 Oct 2022
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance - Yahoo Finance

Tue, 18 Oct 2022
Ikena to examine combination of oncologic with AstraZeneca's Tagrisso for NSCLC (IKNA) - Seeking Alpha

Thu, 06 Oct 2022
Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 14% this week, taking one-year losses to 73% - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 36 (M)
Shares Float 6 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 90.3 (%)
Shares Short 1,560 (K)
Shares Short P.Month 1,720 (K)

Stock Financials

EPS 0.8
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.38
Profit Margin (%) -170.8
Operating Margin (%) -174.5
Return on Assets (ttm) -14.7
Return on Equity (ttm) -28.7
Qtrly Rev. Growth 70.9
Gross Profit (p.s.) -0.45
Sales Per Share 0.83
EBITDA (p.s.) -1.45
Qtrly Earnings Growth 0
Operating Cash Flow -70 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio 2.78
PEG Ratio 0
Price to Book value 0.5
Price to Sales 2.66
Price to Cash Flow -1.16

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.